Compare Stocks: FDMT, VRDN, BCRX, and NKTR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$9.56 -1.0%	$9.63	$6.00 ▼ $11.22	$2.44B	0.55	3.40 million shs	2.48 million shs
FDMT 4D Molecular Therapeutics	$15.83 -1.7%	$11.61	$5.97 ▼ $16.93	$874.51M	2.73	927,760 shs	918,664 shs
NKTR Nektar Therapeutics	$74.02 -0.7%	$69.63	$26.45 ▼ $109.00	$2.53B	1.14	648,431 shs	614,081 shs
VRDN Viridian Therapeutics	$24.29 -0.9%	$19.82	$13.18 ▼ $34.29	$2.75B	0.91	1.87 million shs	905,614 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	0.00%	-1.85%	+1.92%	+15.32%	+14.08%
FDMT 4D Molecular Therapeutics	0.00%	+29.86%	+52.50%	+84.07%	+131.09%
NKTR Nektar Therapeutics	0.00%	+1.37%	+6.72%	+11.12%	+174.66%
VRDN Viridian Therapeutics	0.00%	+10.01%	+26.12%	+40.89%	+33.90%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$9.56 -1.0%	$9.63	$6.00 ▼ $11.22	$2.44B	0.55	3.40 million shs	2.48 million shs
FDMT 4D Molecular Therapeutics	$15.83 -1.7%	$11.61	$5.97 ▼ $16.93	$874.51M	2.73	927,760 shs	918,664 shs
NKTR Nektar Therapeutics	$74.02 -0.7%	$69.63	$26.45 ▼ $109.00	$2.53B	1.14	648,431 shs	614,081 shs
VRDN Viridian Therapeutics	$24.29 -0.9%	$19.82	$13.18 ▼ $34.29	$2.75B	0.91	1.87 million shs	905,614 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	0.00%	-1.85%	+1.92%	+15.32%	+14.08%
FDMT 4D Molecular Therapeutics	0.00%	+29.86%	+52.50%	+84.07%	+131.09%
NKTR Nektar Therapeutics	0.00%	+1.37%	+6.72%	+11.12%	+174.66%
VRDN Viridian Therapeutics	0.00%	+10.01%	+26.12%	+40.89%	+33.90%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.67	Moderate Buy	$20.60	115.48% Upside
FDMT 4D Molecular Therapeutics	2.80	Moderate Buy	$29.63	87.14% Upside
NKTR Nektar Therapeutics	2.69	Moderate Buy	$141.50	91.16% Upside
VRDN Viridian Therapeutics	2.86	Moderate Buy	$38.93	60.27% Upside

Current Analyst Ratings Breakdown

Latest FDMT, VRDN, BCRX, and NKTR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	NKTR Nektar Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$65.00
8/17/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$32.00
8/7/2026	VRDN Viridian Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$35.00 ➝ $36.00
8/7/2026	VRDN Viridian Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $39.00
8/6/2026	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$14.00 ➝ $13.00
8/6/2026	BCRX BioCryst Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$21.00 ➝ $20.00
7/31/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$37.00
7/28/2026	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/22/2026	NKTR Nektar Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$153.00
7/20/2026	FDMT 4D Molecular Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$36.00

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$940.61M	2.60	$1.24 per share	7.71	($1.78) per share	-5.37
FDMT 4D Molecular Therapeutics	$85.21M	10.26	N/A	N/A	$7.38 per share	2.14
NKTR Nektar Therapeutics	$55.23M	45.75	N/A	N/A	$26.45 per share	2.80
VRDN Viridian Therapeutics	$70.85M	38.84	N/A	N/A	$4.98 per share	4.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	$263.86M	-$1.50	N/A	13.28	N/A	-40.90%	-86.89%	66.37%	11/2/2026 (Estimated)
FDMT 4D Molecular Therapeutics	-$140.11M	-$2.63	N/A	N/A	N/A	-194.74%	-41.33%	-35.90%	11/10/2026 (Estimated)
NKTR Nektar Therapeutics	-$164.08M	-$6.70	N/A	N/A	N/A	-287.84%	-37.87%	-25.67%	11/5/2026 (Estimated)
VRDN Viridian Therapeutics	-$342.60M	-$3.37	N/A	N/A	N/A	-505.86%	-72.97%	-42.80%	11/4/2026 (Estimated)

Latest FDMT, VRDN, BCRX, and NKTR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FDMT 4D Molecular Therapeutics	-$1.02	-$1.04	-$0.02	-$1.04	$3.62 million	$3.78 million
8/13/2026	Q2 2026	NKTR Nektar Therapeutics	-$1.97	-$1.23	+$0.74	-$1.23	$10.43 million	$10.13 million
8/6/2026	Q2 2026	VRDN Viridian Therapeutics	-$1.03	-$1.05	-$0.02	-$1.05	$0.06 million	$0.28 million
8/5/2026	Q2 2026	BCRX BioCryst Pharmaceuticals	$0.1542	$0.30	+$0.1458	$0.30	$183.28 million	$218.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
VRDN Viridian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.32	2.29
FDMT 4D Molecular Therapeutics	0.05	8.03	8.03
NKTR Nektar Therapeutics	N/A	10.42	10.21
VRDN Viridian Therapeutics	0.43	16.95	16.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
FDMT 4D Molecular Therapeutics	99.27%
NKTR Nektar Therapeutics	75.88%
VRDN Viridian Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	3.80%
FDMT 4D Molecular Therapeutics	7.90%
NKTR Nektar Therapeutics	2.50%
VRDN Viridian Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	530	255.54 million	245.83 million	Optionable
FDMT 4D Molecular Therapeutics	120	55.24 million	50.88 million	Optionable
NKTR Nektar Therapeutics	220	34.14 million	33.29 million	Optionable
VRDN Viridian Therapeutics	50	113.29 million	110.57 million	Optionable

FDMT, VRDN, BCRX, and NKTR Headlines

Recent News About These Companies

Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT) and Viridian Therapeutics (VRDN)

August 21 at 2:06 PM | theglobeandmail.com

Insider Selling: Viridian Therapeutics (NASDAQ:VRDN) Insider Sells 14,212 Shares

August 21 at 7:37 AM | insidertrades.com

260,000 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Blue Owl Capital Holdings LP

August 21 at 3:35 AM | marketbeat.com

Viridian Therapeutics (NASDAQ:VRDN) Insider Jennifer Tousignant Sells 14,212 Shares

August 20 at 9:07 PM | marketbeat.com

Handelsbanken Fonder AB Invests $834,000 in Viridian Therapeutics, Inc. $VRDN

August 20 at 4:55 AM | marketbeat.com

GSA Capital Partners LLP Invests $903,000 in Viridian Therapeutics, Inc. $VRDN

August 19, 2026 | marketbeat.com

93,414 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Merck & Co. Inc.

August 18, 2026 | marketbeat.com

1,175,906 Shares in Viridian Therapeutics, Inc. $VRDN Bought by Rice Hall James & Associates LLC

August 18, 2026 | marketbeat.com

Bank of America Corp DE Acquires 173,498 Shares of Viridian Therapeutics, Inc. $VRDN

August 18, 2026 | marketbeat.com

Brokerages Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Price Target at $38.93

August 16, 2026 | americanbankingnews.com

Viridian Therapeutics Inc VRDN

August 15, 2026 | morningstar.comM

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 11, 2026 | marketbeat.com

HC Wainwright Has Negative Forecast for VRDN Q3 Earnings

August 10, 2026 | marketbeat.com

Viridian Therapeutics (VRDN) Receives a Buy from LifeSci Capital

August 8, 2026 | theglobeandmail.com

Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says

August 8, 2026 | finance.yahoo.com

Renaissance Technologies LLC Takes $3.97 Million Position in Viridian Therapeutics, Inc. $VRDN

August 8, 2026 | marketbeat.com

Arrowstreet Capital Limited Partnership Has $455,000 Stock Holdings in Viridian Therapeutics, Inc. $VRDN

August 8, 2026 | marketbeat.com

Viridian Therapeutics (NASDAQ:VRDN) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS

August 7, 2026 | marketbeat.com

Truist Financial Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price

August 7, 2026 | marketbeat.com

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

August 6, 2026 | businesswire.com

First Trust Advisors LP Grows Stock Holdings in Viridian Therapeutics, Inc. $VRDN

August 3, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT, VRDN, BCRX, and NKTR Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$9.56 -0.10 (-1.04%)

As of 08/21/2026 04:00 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

4D Molecular Therapeutics NASDAQ:FDMT

$15.83 -0.27 (-1.68%)

As of 08/21/2026 04:00 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Nektar Therapeutics NASDAQ:NKTR

$74.02 -0.51 (-0.68%)

As of 08/21/2026 04:00 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Viridian Therapeutics NASDAQ:VRDN

$24.29 -0.21 (-0.86%)

As of 08/21/2026 04:00 PM Eastern

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FDMT, VRDN, BCRX, and NKTR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FDMT, VRDN, BCRX, and NKTR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FDMT, VRDN, BCRX, and NKTR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT, VRDN, BCRX, and NKTR Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

4D Molecular Therapeutics NASDAQ:FDMT

Nektar Therapeutics NASDAQ:NKTR

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FDMT, VRDN, BCRX, and NKTR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FDMT, VRDN, BCRX, and NKTR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FDMT, VRDN, BCRX, and NKTR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT, VRDN, BCRX, and NKTR Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

4D Molecular Therapeutics NASDAQ:FDMT

Nektar Therapeutics NASDAQ:NKTR

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools